Urology at Renji Hospital Shanghai | CMCS

Expert Urological Care at One of Shanghai's Premier Hospitals

The Department of Urology at Renji Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of Shanghai's most distinguished urology centers, with a national reputation for excellence in robotic and minimally invasive urological surgery, prostate cancer, bladder cancer, kidney cancer, urolithiasis, and the management of complex urological conditions. The department combines outstanding surgical expertise with a world-class research program and a fully integrated multidisciplinary approach, offering international patients access to some of China's most eminent urologists and the latest surgical techniques and medical therapies.

For international patients requiring robotic prostatectomy, kidney-sparing surgery, bladder cancer treatment, stone surgery, or management of a complex urological condition — Renji Hospital's urology department offers an unparalleled combination of surgical expertise, oncological capability, and research leadership. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their urological care journey at Renji Hospital.

About the Department

Renji Hospital's urology department is a national key clinical specialty operating dedicated urology inpatient wards, multiple urological operating theaters with da Vinci robotic surgical systems, a urodynamics laboratory, a stone center with shock wave lithotripsy and endoscopic stone surgery, a urological oncology program, a male health clinic, a female urology and pelvic floor clinic, and works in close collaboration with oncology, nephrology, and radiology through a fully integrated multidisciplinary team.

Faculty members publish regularly in leading urology journals including European Urology, Journal of Urology, BJU International, Urology, and World Journal of Urology.

Conditions Treated

Prostate Cancer

• Localized Prostate Cancer — Active surveillance for low-risk disease (PSA monitoring, MRI, biopsy); robotic-assisted radical prostatectomy (RARP) with nerve-sparing technique for potency preservation; extended pelvic lymph node dissection; focal therapy (HIFU, cryotherapy) for selected patients
• Locally Advanced Prostate Cancer — RARP with extended PLND; adjuvant or salvage radiation therapy; long-term ADT
• Biochemical Recurrence — PSMA PET-CT for recurrence localization; salvage radiation therapy; ADT; enzalutamide/apalutamide for nmCRPC
• Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — ADT + docetaxel; ADT + abiraterone; ADT + enzalutamide; ADT + apalutamide; ADT + darolutamide; triplet therapy (ADT + docetaxel + darolutamide — ARASENS trial)
• Metastatic CRPC (mCRPC) — Abiraterone + prednisone; enzalutamide; cabazitaxel; olaparib/rucaparib for HRR-mutated mCRPC; lutetium-177 PSMA-617 (Pluvicto) for PSMA-positive mCRPC; radium-223 for bone-predominant disease
• Germline Testing — BRCA1/2, ATM, CDK12, and other HRR gene testing; family counseling

Bladder Cancer

• Non-Muscle-Invasive Bladder Cancer (NMIBC) — TURBT with blue light cystoscopy (HAL); intravesical BCG for high-risk NMIBC; intravesical gemcitabine + docetaxel for BCG-unresponsive NMIBC; nadofaragene firadenovec; pembrolizumab for BCG-unresponsive CIS; cretostimogene grenadenorepvec
• Muscle-Invasive Bladder Cancer (MIBC) — Neoadjuvant cisplatin-based chemotherapy (ddMVAC, GC); robotic radical cystectomy with intracorporeal neobladder or ileal conduit; bladder preservation trimodality therapy (TURBT + chemoradiation + durvalumab) for selected patients
• Advanced/Metastatic Urothelial Carcinoma — Gemcitabine + cisplatin or carboplatin; avelumab maintenance; enfortumab vedotin + pembrolizumab (EV-302 — new standard of care); sacituzumab govitecan; erdafitinib for FGFR-altered disease
• Upper Tract Urothelial Carcinoma — Radical nephroureterectomy; adjuvant nivolumab; erdafitinib for FGFR-altered disease

Kidney Cancer (Renal Cell Carcinoma)

• Localized RCC — Robotic partial nephrectomy for nephron-sparing surgery (T1-T2); zero-ischemia and off-clamp techniques for renal function preservation; radical nephrectomy for larger tumors; ablative therapies (RFA, cryoablation) for small renal masses; active surveillance for very small renal masses
• Locally Advanced RCC — Radical nephrectomy with lymph node dissection; adjuvant pembrolizumab for high-risk resected RCC
• Metastatic RCC — Nivolumab + ipilimumab; pembrolizumab + axitinib; nivolumab + cabozantinib; lenvatinib + pembrolizumab; cabozantinib; belzutifan for VHL-associated RCC; nivolumab monotherapy second-line
• Hereditary RCC — VHL disease; hereditary papillary RCC; HLRCC; SDH-deficient RCC; genetic counseling and surveillance

Urolithiasis (Kidney & Ureteral Stones)

• Shock Wave Lithotripsy (SWL) — For renal and ureteral stones ≤2cm; non-invasive outpatient procedure
• Ureteroscopy (URS) & Laser Lithotripsy — Flexible and semi-rigid URS with holmium laser or thulium fiber laser (TFL) for ureteral and renal stones; single-use digital ureteroscopes
• Percutaneous Nephrolithotomy (PCNL) — Standard and mini-PCNL for large renal stones (>2cm) and staghorn calculi; ultra-mini PCNL; tubeless PCNL
• Retrograde Intrarenal Surgery (RIRS) — Flexible ureteroscopy for renal stones; dusting and fragmentation techniques
• Metabolic Stone Evaluation — 24-hour urine collection; stone analysis; dietary and pharmacological prevention

Benign Prostatic Hyperplasia (BPH)

• Medical Management — Alpha-blockers (tamsulosin, silodosin); 5-alpha reductase inhibitors (finasteride, dutasteride); combination therapy; PDE5 inhibitors (tadalafil) for BPH + ED
• Minimally Invasive Surgical Treatments (MIST) — Prostatic urethral lift (UroLift); water vapor thermal therapy (Rezum); temporary implantable nitinol device (iTIND)
• Endoscopic Surgery — Holmium laser enucleation of the prostate (HoLEP); thulium laser enucleation (ThuLEP); bipolar TURP; GreenLight laser vaporization
• Robotic Simple Prostatectomy — For very large prostates (>100g) not amenable to endoscopic enucleation

Male Health & Andrology

• Erectile Dysfunction (ED) — PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil); intracavernosal injection therapy; vacuum erection device; penile prosthesis implantation (inflatable and malleable)
• Male Infertility — Semen analysis; hormonal evaluation; varicocele repair (microsurgical varicocelectomy); TESA/TESE/Micro-TESE for azoospermia; coordination with reproductive medicine for IVF/ICSI
• Testosterone Deficiency — Testosterone replacement therapy (TRT); monitoring and optimization
• Peyronie's Disease — Collagenase clostridium histolyticum (Xiaflex) injections; surgical correction

Female Urology & Pelvic Floor

• Stress Urinary Incontinence (SUI) — Pelvic floor physiotherapy; mid-urethral sling (TVT, TOT); Burch colposuspension; urethral bulking agents
• Overactive Bladder (OAB) — Behavioral therapy; antimuscarinics (solifenacin, tolterodine); beta-3 agonists (mirabegron, vibegron); botulinum toxin injection; sacral neuromodulation (InterStim)
• Pelvic Organ Prolapse — Pelvic floor physiotherapy; pessary; robotic sacrocolpopexy; native tissue repair
• Interstitial Cystitis/Bladder Pain Syndrome — Intravesical instillations; hydrodistension; amitriptyline; pentosan polysulfate

Robotic & Minimally Invasive Urology

• Robotic-Assisted Radical Prostatectomy (RARP) — Nerve-sparing technique; extended PLND; one of Shanghai's most experienced RARP programs
• Robotic Partial Nephrectomy — Zero-ischemia and off-clamp techniques; renal function preservation
• Robotic Radical Cystectomy — Intracorporeal neobladder and ileal conduit; reduced blood loss
• Robotic Pyeloplasty — For UPJ obstruction; superior to open surgery for complex cases
• Robotic Ureteral Reconstruction — For ureteral strictures and injuries; Boari flap and psoas hitch

Why International Patients Choose Renji Urology

• Robotic Surgery Expertise — High-volume robotic prostatectomy, partial nephrectomy, and cystectomy program
• Lu-177 PSMA Therapy — Access to lutetium-177 PSMA-617 for eligible mCRPC patients
• EV + Pembrolizumab — New standard of care for metastatic urothelial carcinoma
• HoLEP/ThuLEP — Laser enucleation of the prostate for BPH; superior to TURP for large prostates
• Reproductive Medicine Integration — Seamless collaboration with Renji's IVF center for male infertility and micro-TESE
• Cost-Effectiveness — World-class urological care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your urological diagnosis, PSA results, imaging (CT, MRI, PSMA PET-CT), biopsy reports, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate urologist based on your condition — prostate cancer, bladder cancer, kidney cancer, stone disease, BPH, or male/female urology.
4. MDT Submission — Where appropriate, we facilitate pre-arrival case review by Renji's urological oncology MDT.
5. Priority Scheduling — We secure a consultation and surgical slot with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near Renji Hospital, and Shanghai airport transfers.
7. Surgical Coordination — Full coordination of pre-operative assessment, robotic surgical admission, and post-operative care.
8. Post-Operative Follow-Up — Pathology report translation, treatment plan interpretation, and remote follow-up coordination after you return home.

Book a Consultation

If you have prostate cancer, bladder cancer, kidney cancer, kidney stones, BPH, or a complex urological condition — CMCS can arrange a specialist consultation with Renji Hospital's urology team in Shanghai.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com